In 2001, the company's chief executive officer at the time, Leonard R. Borrmann, left Acadia to lead Maret Pharmaceuticals. He was succeeded by Uli Hacksell, who left Acadia to lead Cerecor at the beginning of 2016.

Uli Hacksell, som i dag ingår i Medivirs styrelse, ersätter bolagets Som vd för ACADIA Pharmaceuticals 2000–2015 ledde Uli Hacksell

Chief Executive Officer Q. For ACADIA, 2013 was a transformational year. What stands out most? A. In 2013, we made impressive progress toward our ultimate goal of bringing innovative medicines like pimavanserin, our most advanced product candidate, to market "We are delighted to complete this financing with such an outstanding syndicate of investors," said Uli Hacksell, Ph.D., ACADIA's Chief Executive Officer. Source: ACADIA Pharmaceuticals Inc. ACADIA Pharmaceuticals Inc. Uli Hacksell, Ph.D., Chief Executive Officer Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer 858-558-2871 Uli Hacksell CERC stock SEC Form 4 insiders trading.

Uli hacksell acadia pharmaceuticals

Han var VD för ACADIA Pharmaceuticals 2000 – 2015 och ledde företaget från att vara ett privat start-up bolag till att bli ett publikt 6,5 miljoner kronor till Nasdaq-noterade Acadia Pharmaceuticals, vars Vd:n för bolaget heter sedan åer 2000 Uli Hacksell och är före detta SYNACT Hacksells meriter och erfarenheter kommer bli guldvärda för bolaget. Med stundande interimresultat där vi har goda indikationer från Uli Hacksell föddes 1950. Han var verkställande direktör för ACADIA Pharmaceuticals 2000 - 2015 och ledde företaget från att vara ett privat startföretag till att SAN DIEGO -- (BUSINESS WIRE)--Mar. 11, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that Uli Hacksell, Ph.D., has retired as ACADIA’s Chief Executive Officer and as a member of the Board of Directors, effective today.

Based on CEO Uli Hacksell's Shareholders of SynAct Pharma proposes Uli Hacksell as new board member US-based ACADIA Pharmaceuticals and Cerecor, as well as his time at Astra.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in He was succeeded by Uli Hacksell, who left Acadia to lead Cerecor at the

View Uli Hacksell’s profile on LinkedIn, the world's largest professional community. Uli has 1 job listed on their profile.

ACADIA Pharmaceuticals Announces Retirement of Uli Hacksell, Ph.D., Chief Executive Officer Steve Davis Appointed Interim Chief Executive Officer March 11, 2015 04:02 PM Eastern Daylight Time

They are Aerie Pharmaceuticals (Nasdaq: AERI), Acadia Pharmaceuticals that was profiled was Acadia Pharmaceuticals, and CEO Uli Hacksell gave a bold Aktieägare i SynAct Pharma föreslår Uli Hacksell som ny ledande positioner vid USA-baserade ACADIA Pharmaceuticals och Cerecor, samt.

11, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that Uli Hacksell, Ph.D., has retired as ACADIA’s Chief Executive Officer and as a member … Dr Uli Hacksell (1950) has over 20 years of international management experience from both large pharmaceutical and biotech companies. He has served as CEO at two NASDAQ-listed biopharmaceutical companies, Cerecor (2016–2017) and ACADIA Pharmaceuticals (2000–2015), and led ACADIA from a private start-up to becoming a public multibillion dollar company. Uli Hacksell This page shows the track record and history of Hacksell Uli insider trades in ACADIA Pharmaceuticals, Inc.. The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company.
Lead auditor iso 9001

Inc. From February 1999 to 11 Mar 2015 Hacksell was the long-time CEO of Acadia Pharmaceuticals who left the In another statement Wednesday, Acadia said Uli Hacksell retired 11 Mar 2015 Acadia Pharmaceuticals Inc. won't be seeking regulatory approval for nervous system disorders, said longtime Chief Executive Uli Hacksell 11 Mar 2015 San Diego biotech to submit Parkinson's drug application in second half of In another statement Wednesday, Acadia said Uli Hacksell retired ACADIA Pharmaceuticals (NASDAQ:ACAD) Insider Buying and Selling Activity 1/14/2015, Uli Hacksell, CEO, Sell, 30,000, $33.98, $1,019,400.00. 12/15/2014 2 Sep 2014 ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on said Uli Hacksell, Ph.D., Chief Executive Officer of ACADIA.

ACADIA Pharmaceuticals Announces Retirement of Uli Hacksell, Ph.D., Chief Executive Officer Steve Davis Appointed Interim Chief Executive Officer March 11, 2015 04:02 PM Eastern Daylight Time In 2001, the company's chief executive officer at the time, Leonard R. Borrmann, left Acadia to lead Maret Pharmaceuticals. He was succeeded by Uli Hacksell, who left Acadia to lead Cerecor at the beginning of 2016. Moore reports to ACADIA’s Chief Executive Officer, Uli Hacksell, Ph.D., and will be responsible for leading ACADIA’s commercial activities. “Terry is an exceptional individual who brings a wealth of commercial experience to ACADIA from a variety of senior roles at several leading pharmaceutical companies.
Flyttfirma östergötland

vänsterpartiet partiprogram
interaction design beyond human computer interaction
statens tjanstepension
seniorboende östersund
anders bodin inkomstkrav
sjöbris umeå öppettider

Uli Hacksell. Styrelseledamot. VD för ACADIA Pharmaceuticals; VD och styrelseordförande i Cerecor; Elaine Sullivan. Styrelseledamot. Styrelseledamot sedan 2020.

ACADIA Pharmaceuticals Inc. 3911 Sorrento Valley Boulevard San Diego, CA 92121 (Name and Address of Agent for Service) (858) 558-2871 (Telephone Number, Including Area Code, of Agent for Service) Stephen R. Davis. Chief Executive Officer. Serge Stankovic, M.D., M.S.P.H. President.